Johnson pharmacare Limited has strengthened its board of directors with two new appointments, as announced in a regulatory filing dated April 17, 2026. The pharmaceutical company's board meeting approved these strategic additions to enhance its leadership structure and operational capabilities.

Board Meeting Details

The board of directors convened on Friday, April 17, 2026, from 5:15 p.m. to 5:45 p.m. to deliberate on the director appointments. The meeting was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30 requirements.

New Director Appointments

The board approved two significant appointments effective immediately:

Director Profiles and Qualifications

Mr. Nand Kishore Ray brings experience to the board as the newly appointed Non-Executive & Non-Independent Director. Born on January 1, 1956, he is a graduate and son of Mr. Kalewar Ray. His appointment adds non-executive oversight to the company's governance structure.

Mr. Dheeraj Kumar joins as an Executive Director, bringing operational leadership to the board. Born on January 1, 2005, he is also a graduate and son of Mr. Nand Kishor Ray. His executive role will involve direct participation in the company's day-to-day management and strategic decisions.

Regulatory Compliance

Both appointees have submitted declarations of non-debarment as required under SEBI regulations. The declarations confirm that:

• Neither director is debarred from accessing capital markets
• No orders have been passed by SEBI or other authorities preventing them from holding director positions
• Both meet the eligibility criteria for their respective board positions

Corporate Governance Enhancement

These appointments reflect Johnson Pharmacare Limited's commitment to strengthening its corporate governance framework. The addition of both executive and non-executive directors provides a balanced approach to board composition, ensuring effective oversight while maintaining operational agility in the pharmaceutical sector.

Johnson Pharmacare Limited has announced significant changes to its Board of Directors with the resignation of two key members effective April 17, 2026. The pharmaceutical company disclosed these developments in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting and Resignations Approved

The company's Board of Directors convened on April 17, 2026, from 5:15 p.m. to 5:45 p.m. to address the resignation matters. During this meeting, the Board formally approved the resignations of both directors and ensured compliance with all necessary regulatory disclosures.

Director Resignation Details

The resignations involve two directors holding different positions within the company structure:

Both directors cited personal and unavoidable reasons for their resignations. The company has confirmed receipt of written confirmations from both departing directors stating that no other material reasons exist beyond those provided in their resignation letters.

Regulatory Compliance and Disclosures

Johnson Pharmacare Limited made the announcements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive brief profiles of both resigning directors as required by regulatory guidelines.

Additional Directorships

Both Mr. Rajender Parsad and Mr. Umesh Kumar hold professional category directorships in Space Incubatrics Technologies Limited. This information was disclosed as part of the mandatory requirements for director resignation announcements.

Company Information

Johnson Pharmacare Limited operates from its registered office located at Office No. 4-D, Fourth Floor Vardan Tower, Lakhudi Circle, Near Sardar Patel Stadium, Navrangpura, Ahmedabad, Gujarat. The company is incorporated under CIN: L51100GJ1994PLC022388 and maintains its listing compliance through regular Board meetings and timely regulatory disclosures.

The resignations represent routine corporate governance changes, with both directors stepping down for personal reasons while ensuring proper transition and compliance with all applicable regulations.